Strategies for the use of Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors in cancer therapy

Biomolecules

Volumn 2, Issue 4, 2012, Pages 635-649

  Ström, Cecilia E ^a   Helleday, Thomas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer; DNA repair; Poly(ADP ribose) polymerase; Synthetic lethality

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; XRCC1 PROTEIN;

APOPTOSIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CELL SURVIVAL; DNA END JOINING REPAIR; DNA REPAIR; DNA REPLICATION; EPIGENETICS; EXCISION REPAIR; GENE MUTATION; GENE SILENCING; HUMAN; HYPOXIA; MONOTHERAPY; NECROSIS; NEOPLASM; NONHUMAN; OVARY CANCER; REVIEW;

EID: 85016343160     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom2040635     Document Type: Review

References (83)

1. Chambon, P.; Weill, J.D.; Mandel, P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun. 1963, 11, 39-43.
2. Zahradka, P.; Ebisuzaki, K. A shuttle mechanism for DNA-protein interactions. The regulation of poly(adp-ribose) polymerase. Eur. J. Biochem. 1982, 127, 579-585.
3. Uchida, K.; Suzuki, H.; Maruta, H.; Abe, H.; Aoki, K.; Miwa, M.; Tanuma, S. Preferential degradation of protein-bound (adp-ribose)n by nuclear poly(adp-ribose) glycohydrolase from human placenta. J. Biol. Chem. 1993, 268, 3194-3200.
4. Tanuma, S.; Yagi, T.; Johnson, G.S. Endogenous adp ribosylation of high mobility group proteins 1 and 2 and histone h1 following DNA damage in intact cells. Arch. Biochem. Biophys. 1985, 237, 38-42.
5. Martinez-Zamudio, R.; Ha, H.C. Histone adp-ribosylation facilitates gene transcription by directly remodeling nucleosomes. Mol. Cell. Biol. 2012, 32, 2490-2502.
6. Berger, N.A. Poly(adp-ribose) in the cellular response to DNA damage. Radiat. Res. 1985, 101, 4-15.
7. Ha, H.C.; Snyder, S.H. Poly(adp-ribose) polymerase is a mediator of necrotic cell death by atp depletion. Proc. Natl. Acad. Sci. USA 1999, 96, 13978-13982.
8. Liaudet, L.; Pacher, P.; Mabley, J.G.; Virag, L.; Soriano, F.G.; Hasko, G.; Szabo, C. Activation of poly(adp-ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am. J. Respir. Crit. Care Med. 2002, 165, 372-377.
9. Ma, Y.; Chen, H.; He, X.; Nie, H.; Sheng, C.; Wang, Q.; Xia, W.; Ying, W. Nad+ metabolism and nad+-dependent enzymes: Promising therapeutic targets for neurological diseases. Curr. Drug Targets 2012, 13, 222-229.
10. Moroni, F.; Cozzi, A.; Chiarugi, A.; Formentini, L.; Camaioni, E.; Pellegrini-Giampietro, D.E.; Chen, Y.; Liang, S.; Zaleska, M.M.; Gonzales, C.; et al. Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable poly(adp-ribose) polymerase inhibitors. Br. J. Pharmacol. 2012, 165, 1487-1500.
11. Szabo, G.; Liaudet, L.; Hagl, S.; Szabo, C. Poly(adp-ribose) polymerase activation in the reperfused myocardium. Cardiovasc. Res. 2004, 61, 471-480.
12. Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8, 193-204.
13. Fong, P.C.; Boss, D.S.; Yap, T.A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O'Connor, M.J.; et al. Inhibition of poly(adp-ribose) polymerase in tumors from brca mutation carriers. N. Engl. J. Med. 2009, 361, 123-134.
14. Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Helleday, T. Specific killing of brca2-deficient tumours with inhibitors of poly(adp-ribose)polymerase. Nature 2005, 434, 913-917.
15. Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; et al. Targeting the DNA repair defect in brca mutant cells as a therapeutic strategy. Nature 2005, 434, 917-921.
16. Gelmon, K.A.; Hirte, H.W.; Robidoux, A.; Tonkin, K.S.; Tischkowitz, M.; Swenerton, K.; Huntsman, D.; Carmichael, J.; Macpherson, E.; Oza, A.M. Can we define tumors that will respond to parp inhibitors? A phase ii correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J. Clin. Oncol. 2010, 28(suppl. 15s), abstr 3002.
17. Benjamin, R.C.; Gill, D.M. Poly(adp-ribose) synthesis in vitro programmed by damaged DNA. A comparison of DNA molecules containing different types of strand breaks. J. Biol. Chem. 1980, 255, 10502-10508.
18. Lindahl, T.; Satoh, M.S.; Poirier, G.G.; Klungland, A. Post-translational modification of poly(adp-ribose) polymerase induced by DNA strand breaks. Trends Biochem. Sci. 1995, 20, 405-411.
19. Satoh, M.S.; Lindahl, T. Role of poly(adp-ribose) formation in DNA repair. Nature 1992, 356, 356-358.
20. Okano, S.; Lan, L.; Caldecott, K.W.; Mori, T.; Yasui, A. Spatial and temporal cellular responses to single-strand breaks in human cells. Mol. Cell Biol. 2003, 23, 3974-3981.
21. El-Khamisy, S.F.; Masutani, M.; Suzuki, H.; Caldecott, K.W. A requirement for parp-1 for the assembly or stability of xrcc1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 2003, 31, 5526-5533.
22. Strom, C.E.; Johansson, F.; Uhlen, M.; Al-Khalili Szigyarto, C.; Erixon, K.; Helleday, T. Poly (adp-ribose) polymerase (parp) is not involved in base excision repair but parp inhibition traps a single-strand intermediate. Nucleic Acids Res. 2011, 39, 3166-3175.
23. Allinson, S.L.; Dianova, II; Dianov, G.L. Poly(adp-ribose) polymerase in base excision repair: Always engaged, but not essential for DNA damage processing. Acta Biochim. Pol. 2003, 50, 169-179.
24. Parsons, J.L.; Dianova, II; Allinson, S.L.; Dianov, G.L. Poly(adp-ribose) polymerase-1 protects excessive DNA strand breaks from deterioration during repair in human cell extracts. FEBS J. 2005, 272, 2012-2021.
25. D'Silva, I.; Pelletier, J.D.; Lagueux, J.; D'Amours, D.; Chaudhry, M.A.; Weinfeld, M.; Lees-Miller, S.P.; Poirier, G.G. Relative affinities of poly(adp-ribose) polymerase and DNA-dependent protein kinase for DNA strand interruptions. Biochim. Biophys. Acta 1999, 1430, 119-126.
26. Schultz, N.; Lopez, E.; Saleh-Gohari, N.; Helleday, T. Poly(adp-ribose) polymerase (parp-1) has a controlling role in homologous recombination. Nucleic Acids Res. 2003, 31, 4959-4964.
27. Yang, Y.G.; Cortes, U.; Patnaik, S.; Jasin, M.; Wang, Z.Q. Ablation of parp-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene 2004, 23, 3872-3882.
28. Morrison, C.; Smith, G.C.; Stingl, L.; Jackson, S.P.; Wagner, E.F.; Wang, Z.Q. Genetic interaction between parp and DNA-pk in v(d)j recombination and tumorigenesis. Nat. Genet. 1997, 17, 479-482.
29. Audebert, M.; Salles, B.; Calsou, P. Involvement of poly(adp-ribose) polymerase-1 and xrcc1/DNA ligase iii in an alternative route for DNA double-strand breaks rejoining. J. Biol. Chem. 2004, 279, 55117-55126.
30. Wang, M.; Wu, W.; Wu, W.; Rosidi, B.; Zhang, L.; Wang, H.; Iliakis, G. Parp-1 and ku compete for repair of DNA double strand breaks by distinct nhej pathways. Nucleic Acids Res. 2006, 34, 6170-6182.
31. Corneo, B.; Wendland, R.L.; Deriano, L.; Cui, X.; Klein, I.A.; Wong, S.Y.; Arnal, S.; Holub, A.J.; Weller, G.R.; Pancake, B.A.; et al. Rag mutations reveal robust alternative end joining. Nature 2007, 449, 483-486.
32. Wang, H.; Rosidi, B.; Perrault, R.; Wang, M.; Zhang, L.; Windhofer, F.; Iliakis, G. DNA ligase iii as a candidate component of backup pathways of nonhomologous end joining. Cancer Res. 2005, 65, 4020-4030.
33. Li, Z.; Otevrel, T.; Gao, Y.; Cheng, H.L.; Seed, B.; Stamato, T.D.; Taccioli, G.E.; Alt, F.W. The xrcc4 gene encodes a novel protein involved in DNA double-strand break repair and v(d)j recombination. Cell 1995, 83, 1079-1089.
34. Rass, E.; Grabarz, A.; Plo, I.; Gautier, J.; Bertrand, P.; Lopez, B.S. Role of mre11 in chromosomal nonhomologous end joining in mammalian cells. Nature Struct. Mol. Biol. 2009, 16, 819-824.
35. Deriano, L.; Stracker, T.H.; Baker, A.; Petrini, J.H.; Roth, D.B. Roles for nbs1 in alternative nonhomologous end-joining of v(d)j recombination intermediates. Mol. Cell 2009, 34, 13-25.
36. Spagnolo, L.; Barbeau, J.; Curtin, N.J.; Morris, E.P.; Pearl, L.H. Visualization of a DNA-pk/parp1 complex. Nucleic Acids Res. 2012, 40, 4168-4177.
37. Galande, S.; Kohwi-Shigematsu, T. Poly(adp-ribose) polymerase and ku autoantigen form a complex and synergistically bind to matrix attachment sequences. J. Biol. Chem. 1999, 274, 20521-20528.
38. Ariumi, Y.; Masutani, M.; Copeland, T.D.; Mimori, T.; Sugimura, T.; Shimotohno, K.; Ueda, K.; Hatanaka, M.; Noda, M. Suppression of the poly(adp-ribose) polymerase activity by DNA-dependent protein kinase in vitro. Oncogene 1999, 18, 4616-4625.
39. Cheng, Q.; Barboule, N.; Frit, P.; Gomez, D.; Bombarde, O.; Couderc, B.; Ren, G.S.; Salles, B.; Calsou, P. Ku counteracts mobilization of parp1 and mrn in chromatin damaged with DNA double-strand breaks. Nucleic Acids Res. 2011, 39, 9605-9619.
40. Bryant, H.E.; Petermann, E.; Schultz, N.; Jemth, A.S.; Loseva, O.; Issaeva, N.; Johansson, F.; Fernandez, S.; McGlynn, P.; Helleday, T. Parp is activated at stalled forks to mediate mre11-dependent replication restart and recombination. EMBO J. 2009, 28, 2601-2615.
41. Ying, S.; Hamdy, F.C.; Helleday, T. Mre11-dependent degradation of stalled DNA replication forks is prevented by brca2 and parp1. Cancer Res. 2012, 72, 2814-2821.
42. Gottipati, P.; Vischioni, B.; Schultz, N.; Solomons, J.; Bryant, H.E.; Djureinovic, T.; Issaeva, N.; Sleeth, K.; Sharma, R.A.; Helleday, T. Poly(adp-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res. 2010, 70, 5389-5398.
43. Groth, P.; Auslander, S.; Majumder, M.M.; Schultz, N.; Johansson, F.; Petermann, E.; Helleday, T. Methylated DNA causes a physical block to replication forks independently of damage signalling, o(6)-methylguanine or DNA single-strand breaks and results in DNA damage. J. Mol. Biol. 2010, 402, 70-82.
44. Lundin, C.; North, M.; Erixon, K.; Walters, K.; Jenssen, D.; Goldman, A.S.; Helleday, T. Methyl methanesulfonate (mms) produces heat-labile DNA damage but no detectable in vivo DNA double-strand breaks. Nucleic Acids Res. 2005, 33, 3799-3811.
45. Wang, Z.Q.; Auer, B.; Stingl, L.; Berghammer, H.; Haidacher, D.; Schweiger, M.; Wagner, E.F. Mice lacking adprt and poly(adp-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev. 1995, 9, 509-520.
46. Shall, S.; de Murcia, G. Poly(adp-ribose) polymerase-1: What have we learned from the deficient mouse model? Mutat. Res. 2000, 460, 1-15.
47. Conde, C.; Mark, M.; Oliver, F.J.; Huber, A.; de Murcia, G.; Menissier-de Murcia, J. Loss of poly(adp-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice. EMBO J. 2001, 20, 3535-3543.
48. Ame, J.C.; Rolli, V.; Schreiber, V.; Niedergang, C.; Apiou, F.; Decker, P.; Muller, S.; Hoger, T.; Menissier-de Murcia, J.; de Murcia, G. Parp-2, a novel mammalian DNA damage-dependent poly(adp-ribose) polymerase. J. Biol. Chem. 1999, 274, 17860-17868.
49. Menissier de Murcia, J.; Ricoul, M.; Tartier, L.; Niedergang, C.; Huber, A.; Dantzer, F.; Schreiber, V.; Ame, J.C.; Dierich, A.; LeMeur, M.; et al. Functional interaction between parp-1 and parp-2 in chromosome stability and embryonic development in mouse. EMBO J. 2003, 22, 2255-2263.
50. Jagtap, P.; Szabo, C. Poly(adp-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 2005, 4, 421-440.
51. Godon, C.; Cordelieres, F.P.; Biard, D.; Giocanti, N.; Megnin-Chanet, F.; Hall, J.; Favaudon, V. Parp inhibition versus parp-1 silencing: Different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res. 2008, 36, 4454-4464.
52. Curtin, N.J. Parp inhibitors for cancer therapy. Expert Rev. Mol. Med. 2005, 7, 1-20.
53. Helleday, T. The underlying mechanism for the parp and brca synthetic lethality: Clearing up the misunderstandings. Mol. Oncol. 2011, 5, 387-393.
54. Fisher, A.E.; Hochegger, H.; Takeda, S.; Caldecott, K.W. Poly(adp-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(adp-ribose) glycohydrolase. Mol. Cell Biol. 2007, 27, 5597-5605.
55. Patel, A.G.; Sarkaria, J.N.; Kaufmann, S.H. Nonhomologous end joining drives poly(adp-ribose) polymerase (parp) inhibitor lethality in homologous recombination-deficient cells. Proc. Natl. Acad. Sci. USA 2011, 108, 3406-3411.
56. Saintigny, Y.; Delacote, F.; Vares, G.; Petitot, F.; Lambert, S.; Averbeck, D.; Lopez, B.S. Characterization of homologous recombination induced by replication inhibition in mammalian cells. EMBO J. 2001, 20, 3861-3870.
57. Serrano, M.A.; Li, Z.; Dangeti, M.; Musich, P.R.; Patrick, S.; Roginskaya, M.; Cartwright, B.; Zou, Y. DNA-pk, atm and atr collaboratively regulate p53-rpa interaction to facilitate homologous recombination DNA repair. Oncogene 2012, doi:10.1038/onc.2012.257.
58. Tobin, L.A.; Robert, C.; Nagaria, P.; Chumsri, S.; Twaddell, W.; Ioffe, O.B.; Greco, G.E.; Brodie, A.H.; Tomkinson, A.E.; Rassool, F.V. Targeting abnormal DNA repair in therapy-resistant breast cancers. Mol. Cancer Res.: MCR 2012, 10, 96-107.
59. Bartkova, J.; Rezaei, N.; Liontos, M.; Karakaidos, P.; Kletsas, D.; Issaeva, N.; Vassiliou, L.V.; Kolettas, E.; Niforou, K.; Zoumpourlis, V.C.; et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444, 633-637.
60. Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Helleday, T. Specific killing of brca2-deficient tumours with inhibitors of poly(adp-ribose) polymerase. Nature 2005, 434, 913-917.
61. Buisson, R.; Dion-Cote, A.M.; Coulombe, Y.; Launay, H.; Cai, H.; Stasiak, A.Z.; Stasiak, A.; Xia, B.; Masson, J.Y. Cooperation of breast cancer proteins palb2 and piccolo brca2 in stimulating homologous recombination. Nature Struct. Mol. Biol. 2010, 17, 1247-1254.
62. Loveday, C.; Turnbull, C.; Ramsay, E.; Hughes, D.; Ruark, E.; Frankum, J.R.; Bowden, G.; Kalmyrzaev, B.; Warren-Perry, M.; Snape, K.; et al. Germline mutations in rad51d confer susceptibility to ovarian cancer. Nat. Genet. 2011, 43, 879-882.
63. Vilar, E.; Bartnik, C.M.; Stenzel, S.L.; Raskin, L.; Ahn, J.; Moreno, V.; Mukherjee, B.; Iniesta, M.D.; Morgan, M.A.; Rennert, G.; et al. Mre11 deficiency increases sensitivity to poly(adp-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 2011, 71, 2632-2642.
64. McCabe, N.; Turner, N.C.; Lord, C.J.; Kluzek, K.; Bialkowska, A.; Swift, S.; Giavara, S.; O'Connor, M.J.; Tutt, A.N.; Zdzienicka, M.Z.; et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(adp-ribose) polymerase inhibition. Cancer Res. 2006, 66, 8109-8115.
65. Turner, N.; Tutt, A.; Ashworth, A. Hallmarks of 'brcaness' in sporadic cancers. Nat. Rev. Cancer 2004, 4, 814-819.
66. Dedes, K.J.; Wetterskog, D.; Mendes-Pereira, A.M.; Natrajan, R.; Lambros, M.B.; Geyer, F.C.; Vatcheva, R.; Savage, K.; Mackay, A.; Lord, C.J.; et al. Pten deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to parp inhibitors. Science Trans. Med. 2010, 2, 53ra75.
67. Bryant, H.E.; Helleday, T. Inhibition of poly (adp-ribose) polymerase activates atm which is required for subsequent homologous recombination repair. Nucleic Acids Res. 2006, 34, 1685-1691.
68. Hoglund, A.; Stromvall, K.; Li, Y.; Forshell, L.P.; Nilsson, J.A. Chk2 deficiency in myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with parp inhibition. Cell Cycle 2011, 10, 3598-3607.
69. Mitchell, C.; Park, M.; Eulitt, P.; Yang, C.; Yacoub, A.; Dent, P. Poly(adp-ribose) polymerase 1 modulates the lethality of chk1 inhibitors in carcinoma cells. Mol. Pharmacol. 2010, 78, 909-917.
70. Fraser, M.; Zhao, H.; Luoto, K.R.; Lundin, C.; Coackley, C.; Chan, N.; Joshua, A.M.; Bismar, T.A.; Evans, A.; Helleday, T.; et al. Pten deletion in prostate cancer cells does not associate with loss of rad51 function: Implications for radiotherapy and chemotherapy. Clin. Cancer Res. 2012, 18, 1015-1027.
71. Johnson, N.; Li, Y.C.; Walton, Z.E.; Cheng, K.A.; Li, D.; Rodig, S.J.; Moreau, L.A.; Unitt, C.; Bronson, R.T.; Thomas, H.D.; et al. Compromised cdk1 activity sensitizes brca-proficient cancers to parp inhibition. Nat. Med. 2011, 17, 875-882.
72. McLellan, J.L.; O'Neil, N.J.; Barrett, I.; Ferree, E.; van Pel, D.M.; Ushey, K.; Sipahimalani, P.; Bryan, J.; Rose, A.M.; Hieter, P. Synthetic lethality of cohesins with parps and replication fork mediators. PLoS Genetics 2012, 8, e1002574.
73. Taniguchi, T.; Tischkowitz, M.; Ameziane, N.; Hodgson, S.V.; Mathew, C.G.; Joenje, H.; Mok, S.C.; D'Andrea, A.D. Disruption of the fanconi anemia-brca pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 2003, 9, 568-574.
74. Walsh, T.; Casadei, S.; Lee, M.K.; Pennil, C.C.; Nord, A.S.; Thornton, A.M.; Roeb, W.; Agnew, K.J.; Stray, S.M.; Wickramanayake, A.; et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc. Natl. Acad. Sci. USA 2011, 108, 18032-18037.
75. Wickramanyake, A.; Bernier, G.; Pennil, C.; Casadei, S.; Agnew, K.J.; Stray, S.M.; Mandell, J.; Garcia, R.L.; Walsh, T.; King, M.C.; et al. Loss of function germline mutations in rad51d in women with ovarian carcinoma. Gynecol. Oncol. 2012, 127, 552-555.
76. Byers, L.A.; Wang, J.; Nilsson, M.B.; Fujimoto, J.; Saintigny, P.; Yordy, J.; Giri, U.; Peyton, M.; Fan, Y.H.; Diao, L.; et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including parp1. Cancer Discov. 2012, 2, 798-811.
77. Galia, A.; Calogero, A.E.; Condorelli, R.; Fraggetta, F.; La Corte, A.; Ridolfo, F.; Bosco, P.; Castiglione, R.; Salemi, M. Parp-1 protein expression in glioblastoma multiforme. Eur. J. Histochem.: EJH 2012, 56, e9.
78. Rojo, F.; Garcia-Parra, J.; Zazo, S.; Tusquets, I.; Ferrer-Lozano, J.; Menendez, S.; Eroles, P.; Chamizo, C.; Servitja, S.; Ramirez-Merino, N.; et al. Nuclear parp-1 protein overexpression is associated with poor overall survival in early breast cancer. ESMO 2012, 23, 1156-1164.
79. Nosho, K.; Yamamoto, H.; Mikami, M.; Taniguchi, H.; Takahashi, T.; Adachi, Y.; Imamura, A.; Imai, K.; Shinomura, Y. Overexpression of poly(adp-ribose) polymerase-1 (parp-1) in the early stage of colorectal carcinogenesis. Eur. J. Cancer 2006, 42, 2374-2381.
80. Ibrahim, Y.H.; Garcia-Garcia, C.; Serra, V.; He, L.; Torres-Lockhart, K.; Prat, A.; Anton, P.; Cozar, P.; Guzman, M.; Grueso, J.; et al. Pi3k inhibition impairs brca1/2 expression and sensitizes brca proficient triple negative breast cancer to parp inhibition. Cancer Discov. 2012, 2, 1036-1047.
81. Juvekar, A.; Burga, L.N.; Hu, H.; Lunsford, E.P.; Ibrahim, Y.H.; Balmana, J.; Rajendran, A.; Papa, A.; Spencer, K.; Lyssiotis, C.A.; et al. Combining a pi3k inhibitor with a parp inhibitor provides an effective therapy for a mouse model of brca1-related breast cancer. Cancer Discov. 2012, 2, 1048-1063.
82. Kimbung, S.; Biskup, E.; Johansson, I.; Aaltonen, K.; Ottosson-Wadlund, A.; Gruvberger-Saal, S.; Cunliffe, H.; Fadeel, B.; Loman, N.; Berglund, P.; et al. Co-targeting of the pi3k pathway improves the response of brca1 deficient breast cancer cells to parp1 inhibition. Cancer Lett. 2012, 319, 232-241.
83. Chan, N.; Pires, I.M.; Bencokova, Z.; Coackley, C.; Luoto, K.R.; Bhogal, N.; Lakshman, M.; Gottipati, P.; Oliver, F.J.; Helleday, T.; et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res. 2010, 70, 8045-8054.